)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Enliven Therapeutics
Enliven Therapeutics (ELVN) investor relations material
Enliven Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
FDA alignment on ENABLE-2’s final design supports a planned Phase 3 start before year-end 2026; the trial will evaluate relcobatinib in previously treated CML.
Relcobatinib remains the lead clinical program; ELVN-002 development was discontinued and the program is exploring strategic alternatives.
Phase 1 ENABLE data were presented at four hematology meetings; preclinical findings on selectivity and resistant-mutation activity appeared in Leukemia.
Relcobatinib was adopted as the nonproprietary name for ELVN-001; Kristine Ball joined the Board of Directors.
Financial highlights
Q3 2026 operating expenses were $36.0M vs. $25.1M YoY; net loss was $27.7M vs. $20.1M, and loss per share was $0.36 vs. $0.32.
9M 2026 operating expenses were $101.1M vs. $85.4M; net loss was $83.8M vs. $74.0M, and loss per share was $1.21 vs. $1.35.
Cash, cash equivalents and marketable securities totaled $884.4M at September 30, 2026, vs. $462.6M at December 31, 2025.
No product or other revenue has been generated; meaningful revenue is not expected unless product candidates are approved and commercialized.
Outlook and guidance
Cash and marketable securities are expected to fund operations into 2030; a separate filing disclosure says the current operating plan provides at least 12 months of funding from filing.
ENABLE-2 is planned to enroll ~450 adults, randomized 1:1 to relcobatinib 80 mg once daily or investigator-selected dasatinib, nilotinib or bosutinib.
Primary endpoint is MMR at Week 24, potentially supporting accelerated approval; MMR at Week 96 is the key secondary endpoint that could support full approval.
R&D and G&A expenses are expected to increase substantially as clinical development, staffing, manufacturing and potential commercialization needs grow.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Enliven Therapeutics
- ELVN-001 targets a $16B global CML market with best-in-class efficacy and strong clinical momentum.ELVN
Morgan Stanley 24th Annual Global Healthcare Conference - Strong Phase 1 results and FDA alignment set up ENABLE-2 trial, with $895.2M cash runway.ELVNQ2 2026
- ELVN-001 showed high efficacy and safety in CML, advancing to pivotal Phase 3 trials.ELVNStudy update
- Updated phase I CML data and pivotal trial plans position the company for major milestones.ELVNJefferies Global Healthcare Conference 2026
- Advancing a selective TKI for CML with strong data, pivotal trial plans, and robust financial runway.ELVN7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- Q1 2026 net loss was $23.6M; strong cash position supports ELVN-001 development into 2029.ELVNQ1 2026
- Virtual meeting to vote on directors, auditor, share increase, and executive pay proposals.ELVNProxy filing
- Virtual meeting to vote on directors, auditor, share increase, and executive pay, all board-backed.ELVNProxy filing
- Shareholders will vote on key governance, compensation, and capital structure proposals at the annual meeting.ELVNProxy filing
Next Enliven Therapeutics earnings date
Q4 20263 Mar, 2027
Enliven Therapeutics
Next Enliven Therapeutics earnings date
Q4 20263 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for cancer treatment. The company aims to address both existing and emerging unmet needs in oncology with a precision approach designed to improve patient survival and overall well-being. Their development pipeline includes advanced candidates such as ELVN-001 and ELVN-002, which are being explored for their potential to offer enhanced selectivity, combinability, and safety in treatment protocols. The company is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.